Company Overview
Neurogene Inc. operates as a clinical stage biotechnology company dedicated to developing genetic medicines specifically for the treatment of rare neurological diseases. This business model places the firm within the healthcare sector and the biotechnology industry, where value is often derived from the pipeline potential of investigational products rather than immediate commercial revenue streams. The company's current market capitalization stands at $341.24M, supported by a workforce of 131 employees, while its revenue figures are not currently available for the trailing twelve months. These valuation metrics and personnel levels indicate that Neurogene is a mid-sized entity in its sector, relying heavily on future clinical trial outcomes to drive its enterprise value rather than established sales performance. The absence of reported revenue for the trailing twelve months suggests the company is still in a phase of investment and development, typical for firms focused on early-stage genetic therapies like NGN-401 and NGN-101.
Financial Health
The company reported a net income of $-90,351,000 and an EBITDA of $-100,116,000 for the trailing twelve months, while specific revenue data is not available for this period. The substantial gap between the reported net income and EBITDA, both of which are negative, reveals a significant cost structure driven by research and development expenses and operational overheads that exceed current earnings capabilities. Free cash flow for the period was $-46,465,124, indicating that the company is currently burning cash to fund its clinical operations and does not yet possess the financial flexibility to generate positive operating cash flow. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company has not yet achieved commercial profitability or that revenue recognition does not currently cover the direct costs of goods sold. On the balance sheet, the company holds $269.01M in cash against $9.89M in debt, resulting in a debt-to-equity ratio of 3.73, which suggests a leveraged position relative to equity but provides a substantial cash buffer for ongoing expenditures. The current ratio is reported at 16.56, a figure that indicates extremely strong short-term liquidity and the ability to meet its short-term obligations many times over with its liquid assets. Return on equity stands at -31.4% and return on assets is -20.7%, metrics that reveal that management is currently utilizing the company's capital base to generate losses rather than positive returns, a common characteristic in the pre-commercialization biotechnology stage.
Valuation Assessment
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed as -3.43, implying that the market is pricing the stock based on negative expected earnings rather than established profitability. The price-to-book ratio is 1.29, indicating that the market values the company at a 29% premium over its book value, which can reflect expectations of future asset appreciation or intangible value despite current losses. Since the price-to-sales ratio and specific sales data are not available, the EV/EBITDA of -0.84 serves as an alternative valuation metric, suggesting the market is valuing the company slightly above its enterprise value relative to its negative earnings power. The stock's 52-week high was $37.27 and the low was $6.88, placing the current trading position within a highly volatile range that reflects the speculative nature of clinical-stage assets. With a beta of 1.69, the stock exhibits high price volatility relative to the broader market, moving with greater intensity than the general index due to its sensitivity to biotechnology sector shifts and clinical trial results.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both reported as not available, which prevents a direct comparison of earnings acceleration against revenue expansion in the traditional sense. Since the company is not a dividend payer, it does not distribute a dividend yield or maintain a payout ratio, meaning all available capital is retained and reinvested into research and development activities to advance its genetic medicine pipeline. The overall growth and income profile is defined by a lack of current commercial generation, with the company relying entirely on its cash reserves to fund growth initiatives rather than generating income through dividends or sales growth. This reinvestment strategy is standard for biotechnology firms in the clinical stage, where the primary objective is to secure regulatory approval for product candidates like NGN-401 rather than to maximize immediate shareholder yield.